Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.91 and traded as low as $0.61. Seres Therapeutics shares last traded at $0.62, with a volume of 3,849,237 shares.
Wall Street Analysts Forecast Growth
MCRB has been the topic of a number of recent analyst reports. Oppenheimer decreased their target price on Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, March 6th. Chardan Capital cut their target price on Seres Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 6th.
View Our Latest Stock Analysis on Seres Therapeutics
Seres Therapeutics Stock Down 1.4 %
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) last announced its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.08. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.50 million. Equities analysts expect that Seres Therapeutics, Inc. will post -1.15 earnings per share for the current year.
Institutional Trading of Seres Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC purchased a new position in shares of Seres Therapeutics in the 3rd quarter worth about $26,000. Simplicity Solutions LLC bought a new position in shares of Seres Therapeutics in the 3rd quarter worth approximately $27,000. Stifel Financial Corp bought a new position in shares of Seres Therapeutics in the 4th quarter worth approximately $28,000. Wexford Capital LP bought a new position in Seres Therapeutics during the 4th quarter valued at approximately $29,000. Finally, GTS Securities LLC bought a new position in Seres Therapeutics during the 3rd quarter valued at approximately $32,000. 59.34% of the stock is currently owned by institutional investors.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Recommended Stories
- Five stocks we like better than Seres Therapeutics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- United Airlines Soars on Earnings Beat
- How to Calculate Retirement Income: MarketBeat’s Calculator
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.